Results 161 to 170 of about 9,966 (258)

Causes of Drug-Induced Severe Cutaneous Adverse Reaction Epidermal Necrolysis (EN): An Analysis Using FDA Adverse Event Reporting System (FAERS) Database

, 2023
Weiqiang Fei, Jun Shen, Hui Cai
openalex   +2 more sources

Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database

Frontiers in Pharmacology
BackgroundSulfasalazine is a widely used anti-inflammatory medication for treating autoimmune disorders such as ulcerative colitis (UC), Crohn’s disease, and rheumatoid arthritis. However, its safety profile has not been systematically evaluated in real-world settings.
Wangyu Ye, Yuan Ding, Meng Li, Zhihua Tian, Shaoli Wang, Zhen Liu   +5 more
openaire   +3 more sources

Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study

, 2023
Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Carolina Schinke, Anita D’Souza, Meera Mohan   +9 more
openalex   +1 more source

By FAER Means or Foul: The Road to Advancement for the Academic Anesthesiologist

Anesthesia & Analgesia, 2018
Michael R. Mathis, Kevin K. Tremper
openaire   +4 more sources

Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration-FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

, 2023
Stefania Chiappini, Rachel Vickers‐Smith, Daniel R. Harris, Duccio G. Petellier Papanti, John Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, Fabrizio Schifano   +8 more
openalex   +1 more source

The safety analysis of lurasidone based on the real-world data of FAERS database

Expert Opinion on Drug Safety
To assess lurasidone’s real-world safety via retrospective analysis of post-marketing adverse reactions. Signal mining was carried out by retrieving the adverse events (AEs) associated with lurasidone from the FDA Adverse Event Reporting System (FAERS) database spanning from the first quarter of 2011 to the fourth quarter of 2023.
Ziyi Luo, Mengting Zhang, Weijian Liang, Mianda Hu, Yunze Jiang, Xi Lei, Zhenjie Wang, Jinfeng Zhu, Yikuan Du, Yi Liu, Chun Yang   +10 more
openaire   +2 more sources

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases

Drug Design, Development and Therapy, 2015
Kaori Nomura,1 Kunihiko Takahashi,2 Yasushi Hinomura,3 Genta Kawaguchi,4 Yasuyuki Matsushita,5 Hiroko Marui,6 Tatsuhiko Anzai,7 Masayuki Hashiguchi,8 Mayumi Mochizuki8 1Division of Molecular Epidemiology, Jikei University School of Medicine, Tokyo ...
Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M   +8 more
doaj  

SLEEP APNEA ASSOCIATED WITH TICAGRELOR- A PHARMACOVIGILANCE ANALYSIS FROM 2012-2022 FAERS DATABASE

, 2023
Nada Hafez, Omofolarin Babayale, Mohammed Faisaluddin, Asmaa Ahmed   +3 more
openalex   +1 more source

Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names [PDF]

, 2015

core   +1 more source

Analyzing the approach used for cleaning drug names in FAERS database

, 2023
Saam Gough, Hami Piaa
openalex   +2 more sources